Background and aim: Long non-coding RNAs (lncRNAs) are implicated as novel factors in tumorigenesis and tumor progression. Although thousands of lncRNAs have been discovered, only a small portion have been functionally determined in hepatocellular carcinoma (HCC). Here, we aimed to comprehensively analyze differentially expressed lncRNAs, evaluate their clinical significance, and explore the functional roles and underlying mechanism in HCC. Methods: We identified hundreds of lncRNAs which were dysregulated in HCC tissues through performing integrative analyses using the RNA sequencing data and independent gene microarray data from Gene Expression Omnibus and the Cancer Genome Atlas. Results: Dysregulated DUXAP8, LINC01116, LINC01138, and PCAT6 are significantly associated with HCC patients' poor outcomes. Further experimental validation revealed that down-regulation of lncRNA DUXAP8 inhibited HCC cells proliferation and colony formation ability. Mechanistically, DUXAP8 repressed tumor suppressor KLF2 transcription through interacting with histone-lysine N-methyltransferase enzyme enhancer of zeste homolog 2. Conclusion: Taken together, our findings can provide a valuable resource of HCC-associated lncRNAs and new insights into the biological functions of lncRNAs in HCC development.
Introduction
Human hepatocellular carcinoma (HCC), one of the most common gastrointestinal malignancies,is a leading cause of tumor-related deaths worldwide.
1,2 HCC constitutes~80% of all new diagnosed liver cancer cases, and approximately 55% of all HCC patients reside in People's Republic of China. 3 In spite of the great human genome, the rest of which yields thousands of noncoding RNAs including long non-coding RNAs (lncRNAs). 5, 6 LncRNAs are a class of ncRNAs that are >200 nucleotides in length and lack protein-coding ability. 7, 8 Recently, increasing evidence have uncovered the critical roles of lncRNAs in the pathogenesis of diverse cancers with variety of cellular functions, such as cell growth, differentiation, apoptosis, metastasis, and drug resistance. 9, 10 For example, Chen et al found that LINC01234 promoted cell proliferation by acting as miR-204-5p sponge to regulate CBFB expression in gastric cancer. 11 In addition, a novel TGF-β-1-induced lncRNA ELIT-1 promoted epithelial-mesenchymal transition through facilitating TGF-β/Smad signaling by recruiting SMAD3 to the promoters of SNAIL and other TGF-β target genes. 12 Recently, some lncRNAs have been found to contribute to the tumorigenesis and progression of HCC. 13 Up-regulated Lnc-UCID is associated with HCC patients' shorter recurrence-free survival of and promotes cell growth and G1/S transition through competitively binding to DHX9 and sequestering it from CDK6 3ʹUTR region, thereby increasing CDK6 expression. 14 Additionally, overexpressed MCM3AP-AS1 facilitated HCC cells growth and cell cycle transition via sponging miR-194-5p and promoting its target gene FOXA1 expression. 15 Double homeobox A pseudogene 8 (DUXAP8) is a pseudogene derived lncRNA, which is located on chromosome 22q11.1 with 2107 bp in length. A growing number of studies have revealed that DUXAP8 is over expressed and exerts oncogenic function in multiple cancers, including non-small cell lung cancer, 16 gastric cancer, 17 esophageal squamous cell cancer, 18 pancreas cancer, 19 etc.
Highly expressed DUXAP8 contributes to tumor cells proliferation and invasion through interacting with histone demethylase LSD1 or histone methyltransferase EZH2 to repressing tumor suppressors transcription, such as KLF2, EGR1, and PLEKHO. 16, 17 However, the potential functional roles of DUXAP8 in HCC remain unclear. In the present study, we conducted a integrative lncRNA profiling analysis using RNA sequencing data and microarray data in HCC from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Moreover, we determined the cancer promotion function and explored molecular mechanism of lncRNA DUXAP8 in HCC. The findings in this study reveal hundreds of dysregulated lncRNAs in HCC and provide potential useful targets for HCC therapy. 
qRT-PCR assays
The RNeasy Mini Kit (QIAGEN) was used to extract the total RNA of HCC tissues and cells, and 1 μg RNA was reverse-transcribed using the PrimeScript RT Reagent Kit (TaKaRa, Dalian, People's Republic of China) following the manual. For qRT-PCR analysis, we used SYBR Premix Ex Taq regent (TaKaRa) to examine DUXAP8, EZH2, and KLF2 expression levels according to instructions. The sequences of DUXAP8, EZH2, KLF2, and GAPDH primers are: DUXAP8, forward 5ʹ-AGGAT GGAGTCTCGCTGTATTGC-3ʹ, reverse 5ʹ-GGAGGTT TGTTTTCTTCTTTTTT-3ʹ; EZH2, forward 5′-TGC ACATCCTGACTTCTGTG-3′, reverse 5′-AAGGGCA TTCACCAACTCC-3′; KLF2, forward 5′-TTCGG TCTCTTCGACGACG-3′, reverse 5′-TGCGAACTCT TGGTGTAGGTC-3′; GAPDH, forward 5′-AGAAGGC TGGGGCTCATTTG-3′, reverse 5′-AGGGGCCATC CACAGTCTTC-3′.
Cell proliferation assays
The cell proliferation capacity of DUXAP8 or control siRNAs-transfected HCC cells was evaluated with a CCK-8 kit (Dojindo Molecular Technologies, People's Republic of China) according to manual. HepG2 and Hep3B cells transfected with DUXAP8 or scrambled siRNAs were plated into 96-well plates, and 10 μL CCK8 reagent was added in each well.Next, 450 nm absorbance value was measured after incubation for 2 hrs every day. For colony formation assay, HepG2 and Hep3B cells were plated into six-well plates, and cultured for 2 weeks. Finally, 4% paraformaldehyde was used to fix the colonies, which was further stained by 0.1% crystal violet solution.
Subcellular fractionation
The PARIS Kit (Life Technologies) was used to detect the distribution of DUXAP8 in the cytoplasm and nucleus of HepG2 and Hep3B cells according to the manufacturer's manual.
RNA immunoprecipitation (RIP)
The RIP assay was conducted by using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) following the manufacturer's protocol. The IgG antibody was used as a negative control. The SUZ12 and EZH2 antibodies were obtained from the Millipore.
Chromatin immunoprecipitation (ChIP) assay
ChIP experiment was performed with the EZ-ChIP Kit (Millipore) according to the manual, and anti-rabbit IgG was used as a negative control. H3K27me3 and EZH2 antibodies were obtained from Millipore. The primer sequence of KLF2 promoter region is: forward, 5′-ACG GGCTTATTGAGGTTGG-3′; reverse, 5′-GCCTGGGTGA CAGAGGAGAC-3′.
Statistical analyses
The Mann-Whitney U-test, Student's t-test (two-tailed), and one-way analysis were used to analyze the in vitro experimental data on SPSS 18.0. p-value ≤0.05 was determined as significant.
Results

Identification of dysregulated lncRNAs in HCC
To identify more dysregulated lncRNAs in HCC, we downloaded the HCC tissues and normal tissues microarray profiling RNA sequencing data (GSE70880, GSE113850, and GSE124535) from TCGA and GEO. The results of differential profiling analysis indicated that 1938 lncRNAs were altered in TCGA dataset (1295 increased and 643 decreased); 201 lncRNAs were dysregulated in GSE70880 dataset (94 increased and 107 decreased); 101 lncRNAs' expression was altered in GSE113850 dataset (48 increased and 53 decreased); 2162 lncRNAs' expression was altered in GSE124535 dataset (1007 increased and 1155 decreased) ( Figure 1A-D) . Furthermore, Venn analyses indicated that 315 lncRNAs were increased and 383 lncRNAs were decreased in at least two datasets ( Figure 1E ).
Identifying HCC survival-related lncRNAs
To date, increasing evidence have uncovered that lots of lncRNAs are closely related to the outcome of diverse cancers, and can be used as independent predicting factors of patients' prognosis. To identify more HCC outcomerelated lncRNAs, we conducted univariable Cox regression analysis. As showing in Figure 2A , several over expressed and decreased lncRNAs are related to HCC patients shorter OS and PFS (log-rank p<0.05). Taken DUXAP8, LINC01116, LINC01138, and PCAT6, for example, HCC patients with higher expression levels of LINC01116 and DUXAP8 had poorer OS, and HCC patients with higher expression levels of LINC01138 and PCAT6 had poorer PFS ( Figure 2B and C). These findings suggest that these HCC survival-associated lncRNAs may be potential valuable candidates for HCC patients prognosis prediction.
Down-regulation of DUXAP8 impairs HCC cells proliferation
To further determine whether those altered lncRNAs have function in HCC, we chose the over expressed lncRNAs which may be potential biomarkers. We found that DUXAP8 is significantly over expressed in TCGA, GSE70880, and GSE124535 datasets ( Figure 3A ). Moreover, high DUXAP8 level is related to HCC patients' shorter OS. Therefore, DUXAP8 was chosen as a candidate for further validation. Next, the results of qPCR revealed that DUXAP8 expression was significantly upregulated in HCC tissues which is consistent with our analyses results ( Figure 3B ). Moreover, DUXAP8 expression was also increased in HCC cell lines ( Figure 3C ). Next, two siRNAs were used to knock down DUXAP8 expression and the results of qRT-PCR revealed that DUXAP8 expression was decreased by both two siRNAs in HepG2 and Hep3B cells ( Figure 3D) . Furthermore, the results of CCK8 and colony formation assays revealed that DUXAP8 down-regulation impaired HepG2 and Hep3B cells growth and colony formation capacity ( Figure 3E-F) .
DUXAP8 represses KLF2 expression via binding with EZH2
To elucidate the molecular mechanism by which DUXAP8 regulates downstream target genes, we firstly examined distribution of DUXAP8 in HCC cells. The results of cytoplasmic and nuclear fractions showed that DUXAP8 is mainly distributed in HCC cell's nucleus ( Figure 4A) . Furthermore, the results of RIP experiment revealed that DUXAP8 could bind with Figure 4B) . A lot of studies have demonstrated that lncRNAs inhibit some tumor suppressors expression (such as P21 and P51) through binding with EZH2. We found that DUXAP8 downregulation up-regulated KLF2 expression in HCC cells ( Figure 4C ). Meanwhile, down-regulation of EZH2 also up-regulated KLF2 ( Figure 4D) . Furthermore, the results of ChIP experiments revealed that EZH2 could bind to the promoter region of KLF2, and DUXAP8 down-regulation decreased EZH2's binding to KLF2 promoter and H3K27me3 occupancy ( Figure 4E ).
EZH2 in HCC cells (
Discussion
Recently, a lot of large-scale transcriptomics studies using next-generation sequencing and microarray have identified hundreds of dysregulated lncRNAs in multiple cancers. 23, 24 In addition, many evidence demonstrated the involvement of lncRNAs in the biological behavior of tumor cells, including cell proliferation, apoptosis, invasion, metastasis, and drug resistance. 25, 26 In this study, we performed an integrated lncRNAs differential profiling analysis in HCC, and identified hundreds of dysregulated lncRNAs in HCC. Moreover, our findings indicated that some lncRNAs expression levels are correlated with HCC patients shorter survival time, such as DUXAP8, LINC01116, LINC01138, and PCAT6. Our findings identified a lot of abnormally expressed lncRNAs in HCC, and might provide a useful list of lncRNAs for further studies. Among those dysregulated lncRNAs, DUXAP8 was significantly over expressed in HCC and increased DUXAP8 expression is associated with HCC patients poor outcome. Our further experimental validation determined the oncogenic roles of DUXAP8 in HCC cells. In addition to HCC, DUXAP8 has been reported to be over expression in other cancers. Sun et al found that increased DUXAP8 facilitates cells growth and invasion through interacting with EZH2 and LSD1 to Figure 2 Analyzing HCC patients' survival-related lncRNAs. (A) A heatmap was drawn to show the PFS and OS associated lncRNAs-log P-value and hazard ratio value in HCC using the TCGA clinical data. (B) The Kaplan-Meier curve for HCC patients overall survival in high-or low-DUXAP8 and LINC01116 groups using the TCGA data was conducted with two-sided log-rank test. (C) The Kaplan-Meier curve for HCC patients PFS in high-or low-PCAT6 and LINC01138 groups using the TCGA data was conducted with two-sided log-rank test. Abbreviations: IncRNAs, long non-coding RNAs; HCC, hepatocellular carcinoma; TCGA, the Cancer Genome Atlas; PFS, progression-free survival; OS, overall survival.
suppress RHOB and EGR1 expression in non-small cell lung cancer. 16 Moreover, elevated DUXAP8 contributes to renal cell carcinoma development and progression via enhances cells growth through sponging miR-126 to antagonize its repression of CED-9. 27 However, the underlying molecular mechanism of DUXAP8 response for its oncogenic function in HCC remains unclear. Generally, lncRNAs can regulate cancer cells biological behavior through diverse mechanisms, such as acting as microRNAs sponge, binding with RNA-binding proteins and inducing the epigenetic modification, and influencing mRNA stability and translation. [28] [29] [30] Here, our findings indicate that DUXAP8 is mostly located in the cytoplasmic fraction of HCC cells and can bind with histone methyltransferase EZH2, which is consistent with previous studies. Moreover, we found that down-regulation of DUXAP8 or EZH2 could increase tumor suppressor KLF2 expression in HCC cells. Moreover, ChIP assays determined the occupancy of EZH2 and in the promoter regions of KLF2. EZH2 (enhancer of zeste homolog 2) is a subunit of the Polycomb Repressive Complex 2, which is involved in the transcriptional repression of genes. Recently, dysregulation of EZH2 has been frequently observed in multiple cancers, which promotes tumorigenesis through repressing the transcription of numerous tumor suppressor genes. 31 Our findings suggest that the DUXAP8/EZH2/KLF2 axis may be a key molecular mechanism of HCC tumorigenesis and progression. Taken together, this study uncovers hundreds of differentially expressed lncRNAs in HCC, while majority of these lncRNAs biological functions remain unclear. In addition, a small part of those lncRNAs is related to the HCC patients prognosis.
Our findings may provide potential valuable lncRNA candidates as prognostic biomarkers and therapeutic targets for HCC. OncoTargets and Therapy
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